J & J, Legend say Carvykti beat standard therapy in earlier-line blood cancer

J&J and Leg­end Biotech’s next step in turn­ing their CAR-T ther­a­py Carvyk­ti in­to a po­ten­tial megablock­buster has suc­ceed­ed, the com­pa­nies said Fri­day. Carvyk­ti achieved the pri­ma­ry end­point — pro­gres­sion-free sur­vival — in an open-la­bel Phase III study test­ing the treat­ment…#biotechs #carvykti #cartitude4 #carvyktisability #compete #bristol #squibb #bigpharma #refractorymm #anticipated

Source: Reuters: Health - January 28, 2023 Category: Consumer Health News Source Type: news